Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III EOS trial in 933 patients showed that once-daily 500 ug oral Daxas plus Serevent salmeterol for 24 weeks significantly improved mean pre- and post-bronchodilator FEV1 by 49 and 60 mL, respectively, vs. placebo plus

Read the full 428 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE